anti cancer medicine

Palbolieva 125mg Capsule: Maximum Potency CDK4/6 Inhibition for Advanced HR+/HER2- Breast Cancer Care Are you searching for a verified Palbolieva 125mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted breast cancer therapies. We provide a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that high-dose cyclin-dependent kinase inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Palbolieva 125mg? Palbolieva 125mg is an oral targeted chemotherapy medication containing the active pharmaceutical ingredient Palbociclib. Manufactured by Allieva, the 125mg strength is the standard therapeutic starting dose for most patients. It belongs to a revolutionary class of drugs called CDK4/6 inhibitors, designed to specifically block the proteins that drive the rapid division of hormone-receptor-positive breast cancer cells. 1. Therapeutic Indications HR+, HER2- Metastatic Breast Cancer: For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread. Initial Endocrine-Based Therapy: Often prescribed in combination with an aromatase inhibitor (like Letrozole or Anastrozole) as a first-line treatment for postmenopausal women or men. Progressive Disease Therapy: Used in combination with Fulvestrant for patients whose cancer has progressed after prior endocrine therapy. 2. Mechanism of Action: Arresting the Malignant Cell Cycle Kinase Blockade: It selectively inhibits Cyclin-Dependent Kinases 4 and 6 (CDK4/6). In many breast cancers, these kinases are overactive, pushing cells to divide uncontrollably. G1-Phase Arrest: By blocking these enzymes, Palbolieva prevents the cancer cell from moving from the growth phase (G1) to the DNA replication phase (S). Halting Proliferation: This results in “cell cycle arrest,“ which stabilizes the tumor, reduces its size, and significantly extends progression-free survival (PFS). 3. Administration and Dosing Schedule Standard Regimen: Typically administered in a 28-day cycle—one 125mg capsule daily for 21 consecutive days, followed by 7 days of rest. Bioavailability: Palbolieva 125mg should be taken with food at approximately the same time each day to ensure the drug is absorbed correctly by the body. Handling: Capsules must be swallowed whole; they should not be opened, crushed, or chewed. Clinical Side Effects & Safety Monitoring Neutropenia: A significant decrease in white blood cells (neutrophils) is common. Regular complete blood counts (CBC) are mandatory before starting each cycle. Infection Risk: Due to lower blood counts, patients must monitor for signs of fever or chills. Gastrointestinal: Nausea, diarrhea, and mouth sores (stomatitis) are frequently observed. General Fatigue: Significant tiredness or lack of energy is a known clinical side effect. Dermatological: Potential for thinning of the hair (alopecia) or dry skin. Drug Interactions: Avoid grapefruit products and certain herbal supplements like St. John’s Wort, as they can alter the drug's efficacy and toxicity levels. Why Source Palbolieva 125mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Palbolieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, specialty oncology pharmacies, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Palbolieva 100mg Capsule: Breakthrough CDK4/6 Inhibition for Advanced HR+/HER2- Breast Cancer Care Are you searching for a verified Palbolieva 100mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted breast cancer therapies. We provide a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical cyclin-dependent kinase inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Palbolieva 100mg? Palbolieva 100mg is an oral targeted therapy containing the active pharmaceutical ingredient Palbociclib. Manufactured by Allieva, this 100mg capsule is a potent CDK4/6 inhibitor. It has revolutionized the treatment landscape for hormone-driven breast cancers by specifically targeting the machinery that allows cancer cells to divide and multiply. 1. Therapeutic Indications HR+, HER2- Advanced Breast Cancer: For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic). First-Line Combination Therapy: Frequently used in combination with an aromatase inhibitor (such as Letrozole) as the initial endocrine-based therapy for postmenopausal women. Second-Line Combination Therapy: Prescribed in combination with Fulvestrant for patients whose disease has progressed following prior endocrine therapy. 2. Mechanism of Action: Arresting the Cell Cycle Enzyme Inhibition: It targets two specific proteins called cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These proteins are often overactive in breast cancer cells. Phase Arrest: By blocking these kinases, Palbolieva prevents the cancer cell from progressing from the G1 phase to the S phase of the cell cycle. Proliferation Stop: This effectively locks the cancer cell in a non-dividing state, significantly slowing down tumor growth and delaying disease progression. 3. Administration and Dosing Cycle Management: Typically taken in a 21-day on, 7-day off cycle. This rest period allows the body's healthy cells, particularly blood cells, to recover. Timing: Palbolieva 100mg should be taken with food at approximately the same time each day to ensure optimal absorption. Consistency: Adherence to the prescribed cycle is vital for maintaining the “cell cycle arrest“ required to shrink or stabilize tumors. Clinical Side Effects & Safety Monitoring Neutropenia: The most common side effect is a decrease in white blood cells (Neutropenia). Regular complete blood counts (CBC) are mandatory before each cycle to monitor infection risk. Infections: Due to lowered blood counts, patients may be more susceptible to infections. Report fever or chills immediately. Gastrointestinal: Nausea, diarrhea, and stomatitis (mouth sores) are frequently observed clinical side effects. Dermatological: Potential for thinning of the hair (alopecia) or skin rashes. Fatigue & Dizziness: Significant tiredness (asthenia) or dizziness may occur, impacting daily activities. Precautions: Avoid grapefruit and grapefruit juice, as they can interfere with how the body processes the medication, leading to increased toxicity. Why Source Palbolieva 100mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Palbolieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Wholesale Fulfillment: Competitive bulk pricing and steady inventory for hospital groups, breast cancer specialty clinics, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Enzalieva 40mg Capsule: Advanced Androgen Receptor Inhibition for Global Prostate Cancer Care Are you searching for a verified Enzalieva 40mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical androgen receptor inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Enzalieva 40mg? Enzalieva 40mg is an oral targeted therapy containing the active pharmaceutical ingredient Enzalutamide. Manufactured by Allieva, this 40mg capsule is a potent, non-steroidal androgen receptor inhibitor. It is a cornerstone treatment in modern uro-oncology, specifically designed to combat prostate cancer by blocking the hormones that fuel tumor growth, even when traditional hormone therapies have failed. 1. Therapeutic Indications Metastatic Castration-Resistant Prostate Cancer (mCRPC): For patients whose cancer has spread and no longer responds to surgical or medical treatments that lower testosterone. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): For patients whose cancer has not spread but is at high risk of progressing despite androgen deprivation therapy. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Used in combination with androgen deprivation therapy for patients with metastatic disease that still responds to hormone suppression. 2. Mechanism of Action: The Triple-Blockade Strategy Binding Inhibition: It competitively inhibits the binding of androgens (like testosterone) to the androgen receptors within the prostate cancer cells. Nuclear Translocation Inhibition: It prevents the androgen receptor from moving into the cell nucleus, a critical step required for cancer cell signaling. DNA Binding Inhibition: Even if the receptor reaches the nucleus, Enzalieva prevents it from binding with DNA, effectively “turning off“ the genetic instructions that tell the cancer cell to grow and divide. 3. Administration and Dosing Standard Dosage: The typical dose is 160mg (four 40mg capsules) taken once daily. Consistency: It can be taken with or without food. Maintaining a daily routine at the same time is essential for therapeutic efficacy. Handling: Capsules must be swallowed whole and should not be chewed, dissolved, or opened. Clinical Side Effects & Safety Monitoring Fatigue: Significant tiredness or lack of energy is the most commonly reported side effect. Gastrointestinal: Decreased appetite, constipation, or diarrhea. Musculoskeletal: Back pain, joint pain (arthralgia), and an increased risk of falls or fractures. Neurological Risks: While rare, there is a potential risk of seizures; patients with a history of brain injury or seizures should be monitored closely. Cardiovascular: Potential for high blood pressure (hypertension) and ischemic heart disease. General: Hot flushes and peripheral edema (swelling of the extremities). Why Source Enzalieva 40mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Enzalieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, urology networks, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Pariblieva 150mg Tablet: Advanced PARP Inhibition for Targeted Ovarian and Breast Cancer Therapy Are you looking for a verified Pariblieva 150mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical PARP inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Pariblieva 150mg? Pariblieva 150mg is an oral targeted therapy containing the active pharmaceutical ingredient Olaparib. Manufactured by Allieva, this 150mg tablet belongs to a revolutionary class of drugs known as Poly (ADP-ribose) Polymerase (PARP) inhibitors. It is specifically designed for patients with certain genetic mutations, offering a precision medicine approach to treating cancers that have become resistant to traditional chemotherapy. 1. Therapeutic Indications Ovarian Cancer: As maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Breast Cancer: For patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy. Pancreatic Cancer: As maintenance treatment for adult patients with deleterious gBRCAm metastatic pancreatic adenocarcinoma. Prostate Cancer: For patients with metastatic castration-resistant prostate cancer (mCRPC) and specific gene mutations who have progressed following prior therapy. 2. Mechanism of Action: The Concept of Synthetic Lethality Inhibiting DNA Repair: PARP enzymes are responsible for repairing single-strand breaks in DNA. Pariblieva blocks these enzymes. Creating Double-Strand Breaks: When PARP is inhibited, single-strand breaks turn into double-strand breaks during cell replication. Synthetic Lethality: In normal cells, these breaks are repaired via “Homologous Recombination.“ However, in cancer cells with BRCA1 or BRCA2 mutations, this repair pathway is broken. The accumulation of DNA damage becomes too great, and the cancer cell dies, while healthy cells remain largely unaffected. 3. Administration and Dosing Standard Dosage: Typically 300 mg (two 150mg tablets) taken twice daily. Timing: Can be taken with or without food. Tablets should be swallowed whole and not chewed, crushed, or dissolved. Consistency: Maintaining a steady level of the drug in the system is vital for preventing cancer cell DNA repair. Clinical Side Effects & Safety Monitoring Hematological Toxicity: Potential for Anemia, Neutropenia, and Thrombocytopenia. Monthly blood counts (CBC) are recommended for the first year of treatment. Gastrointestinal: Nausea, vomiting, diarrhea, and loss of appetite are common, especially during the first few weeks. Fatigue: Significant tiredness or weakness (asthenia) is frequently reported. MDS/AML: In rare cases, PARP inhibitors have been linked to secondary bone marrow disorders; long-term monitoring of blood counts is essential. Pneumonitis: Rare but serious lung inflammation; patients should report any new or worsening respiratory symptoms immediately. Why Source Pariblieva 150mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Pariblieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, oncology networks, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation to ensure the highest quality standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Lenvalieva 10mg Capsule: High-Potency Multi-Kinase Inhibition for Advanced Oncology Sourcing Are you searching for a verified Lenvalieva 10mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that high-potency multi-kinase inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Lenvalieva 10mg? Lenvalieva 10mg is an oral targeted therapy containing the active pharmaceutical ingredient Lenvatinib. Manufactured by Allieva, the 10mg capsule is a critical strength used in the management of several aggressive malignancies. As a potent kinase inhibitor, it works by interfering with the specific proteins that cancer cells use to grow, divide, and develop the blood vessels they need to survive. 1. Therapeutic Indications Differentiated Thyroid Cancer (DTC): For patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC. Renal Cell Carcinoma (RCC): Used in combination with Everolimus for patients with advanced kidney cancer after one prior anti-angiogenic therapy. It is also a first-line option when combined with Pembrolizumab. Hepatocellular Carcinoma (HCC): As a first-line systemic therapy for patients with unresectable liver cancer. Endometrial Carcinoma: In combination with Pembrolizumab for advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). 2. Mechanism of Action: Triple-Pathway Inhibition Anti-Angiogenesis: It blocks Vascular Endothelial Growth Factor Receptors (VEGFR1, 2, and 3). By preventing the formation of new blood vessels, it “starves“ the tumor of oxygen and nutrients. Blocking Fibroblast Signaling: It inhibits Fibroblast Growth Factor Receptors (FGFR1, 2, 3, and 4), which are often involved in tumor resistance to other therapies. Interrupting Growth Signals: It targets PDGFRα, KIT, and RET, halting the internal signaling pathways that tell cancer cells to multiply rapidly. 3. Administration and Dosage Usage: Taken once daily at the same time each day, with or without food. Dose Titration: The 10mg strength is vital for achieving higher daily dosages (such as 14mg, 18mg, 20mg, or 24mg) as required by specific clinical protocols for Thyroid or Renal cancer. Storage: Store at room temperature (below 30°C) in a dry place. Clinical Side Effects & Safety Monitoring Hypertension: High blood pressure is a frequent side effect; blood pressure must be optimized before starting therapy and monitored weekly. Gastrointestinal: Diarrhea, nausea, vomiting, decreased appetite, and weight loss. Fatigue: Significant tiredness or lack of energy is commonly reported. Dermatological: Palmar-plantar erythrodysesthesia (Hand-Foot Syndrome), characterized by redness, pain, or swelling on the palms and soles. Proteinuria: Potential for protein in the urine; regular urinalysis is recommended. Hepatotoxicity: Rare but serious liver damage; periodic liver function tests (LFTs) are mandatory. Cardiovascular Risks: Increased risk of arterial thromboembolic events (blood clots). Why Source Lenvalieva 10mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Lenvalieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, oncology networks, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation to ensure the highest quality standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Lenvalieva 4mg Capsule: Multi-Kinase Inhibition for Advanced Thyroid, Renal, and Hepatic Cancer Care Are you searching for a verified Lenvalieva 4mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We facilitate a secure, temperature-controlled supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical multi-kinase inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Lenvalieva 4mg? Lenvalieva 4mg is an oral targeted therapy containing the active pharmaceutical ingredient Lenvatinib. Manufactured by Allieva, this 4mg capsule belongs to the class of drugs known as kinase inhibitors. It is a sophisticated precision medicine designed to inhibit specific proteins that cancer cells use to multiply and develop the blood vessels required for tumor survival and expansion. 1. Therapeutic Indications Differentiated Thyroid Cancer (DTC): For patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC. Renal Cell Carcinoma (RCC): Used in combination with Everolimus for patients with advanced kidney cancer following one prior anti-angiogenic therapy. It is also used as a first-line treatment in combination with Pembrolizumab. Hepatocellular Carcinoma (HCC): As a first-line therapy for patients with unresectable liver cancer. Endometrial Carcinoma: Used in combination with Pembrolizumab for advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). 2. Mechanism of Action: Blocking the Pathways of Growth Angiogenesis Inhibition: It blocks the Vascular Endothelial Growth Factor Receptors (VEGFR1, 2, and 3), effectively cutting off the blood supply that tumors need to grow. Blocking Growth Signals: It inhibits Fibroblast Growth Factor Receptors (FGFR1, 2, 3, and 4) and Platelet-Derived Growth Factor Receptor alpha (PDGFRα), which are critical in tumor signaling and survival. Halting Mutation Signaling: It targets the RET and KIT proto-oncogenes, which are often involved in the uncontrolled growth of cancer cells. 3. Administration and Dosing Usage: Usually taken once daily, with or without food. Consistency: The capsule should be taken at the same time every day to maintain a steady concentration in the bloodstream. Dosage Adjustments: The 4mg strength is essential for precise dose titration, allowing oncologists to manage patient responses and minimize side effects by adjusting the number of capsules per day. Clinical Side Effects & Safety Monitoring Hypertension: High blood pressure is a very common side effect and must be controlled before starting treatment and monitored throughout. Gastrointestinal: Diarrhea, nausea, vomiting, decreased appetite, and weight loss. Fatigue: Significant tiredness or lack of energy. Dermatological: Palmar-plantar erythrodysesthesia (Hand-Foot Syndrome), characterized by redness, pain, or swelling on the palms and soles. Proteinuria: Presence of protein in the urine, requiring regular urinalysis. Cardiovascular: Potential for cardiac dysfunction or blood clots; patients with a history of heart issues require extra caution. Hepatotoxicity: Rare but serious liver damage; periodic liver function tests (LFTs) are mandatory. Why Source Lenvalieva 4mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Lenvalieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, specialty clinics, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation to ensure quality standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Temalieva 100mg Capsule: Precision Oral Chemotherapy for Global Neuro-Oncology Sourcing Are you searching for a verified Temalieva 100mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced neuro-oncology medications. We provide a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical alkylating agents reach specialized treatment centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Temalieva 100mg? Temalieva 100mg is an oral chemotherapy medication containing the active pharmaceutical ingredient Temozolomide. Manufactured by Allieva, this 100mg capsule belongs to the class of drugs known as alkylating agents. It is a cornerstone therapy in modern neuro-oncology due to its unique ability to cross the blood-brain barrier, making it highly effective against primary central nervous system (CNS) tumors. 1. Therapeutic Indications Glioblastoma Multiforme (GBM): Used in combination with radiotherapy for newly diagnosed patients and as maintenance therapy thereafter. Anaplastic Astrocytoma: Indicated for adult patients whose tumors have relapsed or progressed following standard chemotherapy. Refractory Gliomas: For various high-grade gliomas that have shown resistance to previous lines of treatment. 2. Mechanism of Action: The DNA Alkylation Process Spontaneous Conversion: Unlike many drugs that require liver metabolism, Temozolomide spontaneously converts at physiological pH to its active metabolite, MTIC. DNA Methylation: MTIC attaches methyl groups to the DNA (specifically at the O6 and N7 positions of guanine). Programmed Cell Death: This methylation creates “mismatches“ in the DNA strand. When the cancer cell attempts to repair this damage, it triggers a signaling cascade that leads to apoptosis (cell death), effectively stopping the tumor from growing. 3. Administration and Dosing Guidelines Standard Cycle: Often prescribed in a 28-day cycle (e.g., daily dosing for 5 days followed by a 23-day rest period, or daily during radiation). Timing: To maximize absorption and reduce nausea, it is recommended to take Temalieva on an empty stomach or at bedtime. Handling: Capsules must be swallowed whole. Do not open or chew them. If a capsule becomes damaged, avoid contact with the powder. Clinical Side Effects & Safety Monitoring Hematological Toxicity: Potential for Thrombocytopenia (low platelets) and Neutropenia (low white blood cells). Regular blood counts (CBC) are mandatory to monitor bone marrow function. Gastrointestinal: Nausea and vomiting are common, particularly during the first few days of a cycle; anti-emetic medications are typically prescribed. General: Fatigue, headache, constipation, and loss of appetite. Hepatotoxicity: Rare instances of liver enzyme elevation; periodic liver function tests (LFTs) are recommended. Pneumocystis Jirovecii Pneumonia (PJP): Patients receiving the drug alongside radiotherapy may require prophylaxis for this specific type of pneumonia. Why Source Temalieva 100mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Temalieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, neurology networks, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and comprehensive B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Lenalieva 10mg Capsule: Advanced Immunomodulatory Therapy for Global Hematology Sourcing Are you searching for a verified Lenalieva 10mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted hematology medications. We provide a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical immunomodulatory treatments reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Lenalieva 10mg? Lenalieva 10mg is an oral targeted therapy containing the active pharmaceutical ingredient Lenalidomide. Manufactured by Allieva, this 10mg capsule belongs to the class of medications known as immunomodulatory agents (IMiDs). It is a cornerstone in the treatment of various plasma cell dyscrasias and certain blood disorders, offering a multi-pathway approach to halting cancer progression and stimulating the body's natural defenses. 1. Therapeutic Indications Multiple Myeloma (MM): Used as maintenance therapy in patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. It is also used in combination with Dexamethasone for relapsed or refractory cases. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): For patients whose disease has relapsed or progressed after two prior therapies, one of which included Bortezomib. Follicular Lymphoma & Marginal Zone Lymphoma: In combination with a Rituximab product for previously treated adult patients. 2. Mechanism of Action: Targeted Biological Attack Immune Stimulation: It enhances the activation of T-cells and Natural Killer (NK) cells, significantly improving the body’s innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It inhibits the growth of new blood vessels within the bone marrow, effectively “starving“ the tumor of the nutrients and oxygen it needs to expand. Direct Tumor Suppression: It binds directly to the Cereblon E3 ubiquitin ligase complex, leading to the degradation of essential proteins required for the survival of malignant B-cells. 3. Administration and Dosing Cycle Management: Often prescribed in a 28-day cycle (e.g., 21 days of treatment followed by a 7-day rest period). Timing: The capsule should be taken at approximately the same time each day, with or without food. Handling: Capsules must be swallowed whole. They should not be opened, broken, or chewed due to the risk of exposure to the active powder. Clinical Side Effects & Safety Monitoring Hematological Toxicity: High risk of Neutropenia (low white blood cells) and Thrombocytopenia (low platelets). Frequent blood counts are mandatory during the early cycles. Venous Thromboembolism: Increased risk of deep vein thrombosis (DVT) and pulmonary embolism. Prophylactic anticoagulation is often recommended. Teratogenicity: CRITICAL WARNING: Lenalidomide is structurally related to thalidomide and can cause severe, life-threatening birth defects. Strict adherence to a regulated pregnancy prevention program is mandatory for all patients. Gastrointestinal: Diarrhea, constipation, nausea, and abdominal pain. General: Fatigue, muscle cramps, and skin rashes Why Source Lenalieva 10mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Lenalieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and comprehensive B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Lenalieva 25mg Capsule: High-Potency Immunomodulatory Therapy for Global Hematology Sourcing Are you searching for a verified Lenalieva 25mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced hematology medications. We provide a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical immunomodulatory treatments reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Lenalieva 25mg? Lenalieva 25mg is an oral targeted therapy containing the active pharmaceutical ingredient Lenalidomide. Manufactured by Allieva, the 25mg strength is the highest standard dosage form, primarily used in intensive treatment phases for plasma cell dyscrasias and certain aggressive blood cancers. As a potent immunomodulatory agent (IMiD), it re-engineers the body’s biological response to malignant cells. 1. Therapeutic Indications Multiple Myeloma (MM): Combined with Dexamethasone as a standard of care for patients with newly diagnosed MM, or those who have relapsed after prior therapies. Mantle Cell Lymphoma (MCL): For patients whose disease has relapsed or progressed following two prior therapies, including at least one proteasome inhibitor. Myelodysplastic Syndromes (MDS): For the treatment of transfusion-dependent anemia in patients with low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Follicular & Marginal Zone Lymphoma: Used in combination with Rituximab for adult patients previously treated for these subtypes of Non-Hodgkin Lymphoma. 2. Mechanism of Action: The Multi-Pathway Defense Direct Cytotoxicity: It binds to the Cereblon E3 ubiquitin ligase complex, triggering the degradation of essential transcription factors (Ikaros and Aiolos) that myeloma cells need to survive. Immune Stimulation: It significantly enhances the activity of T-cells and Natural Killer (NK) cells, empowering the patient's own immune system to detect and destroy cancer cells. Anti-Angiogenesis: It blocks the growth of new blood vessels in the bone marrow, effectively “starving“ the tumor of the nutrients and oxygen required for growth. 3. Administration and Dosing Standard Cycle: Typically prescribed in a 28-day cycle (e.g., 21 days on, 7 days off). Timing: Capsules should be taken at the same time each day, with or without food. Handling: Capsules must be swallowed whole. They should not be opened, crushed, or chewed due to the risk of powder exposure. Clinical Side Effects & Safety Monitoring Hematological Toxicity: A high risk of Neutropenia (low white blood cells) and Thrombocytopenia (low platelets). Frequent blood counts are mandatory. Venous Thromboembolism: Increased risk of deep vein thrombosis (DVT) and pulmonary embolism. Prophylactic blood thinners are usually recommended. Teratogenicity: CRITICAL WARNING: Lenalidomide is structurally related to thalidomide and can cause severe, life-threatening birth defects. Strict adherence to regulated pregnancy prevention programs is mandatory. Gastrointestinal: Diarrhea, constipation, nausea, and abdominal pain. General: Fatigue, muscle cramps, and skin rashes. Why Source Lenalieva 25mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Lenalieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and comprehensive B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Lenalieva 5mg Capsule: Precision Immunomodulatory Therapy for Global Hematology Sourcing Are you searching for a verified Lenalieva 5mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced hematology medications. We provide a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical immunomodulatory treatments reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Lenalieva 5mg? Lenalieva 5mg is an oral targeted therapy containing the active pharmaceutical ingredient Lenalidomide. Manufactured by Allieva, this 5mg capsule belongs to a class of medications known as immunomodulatory agents (IMiDs). It is a cornerstone in the treatment of various plasma cell dyscrasias and certain blood disorders, offering a multi-pathway approach to halting cancer progression. 1. Therapeutic Indications Multiple Myeloma (MM): Used in combination with Dexamethasone for patients who have received at least one prior therapy, and as a maintenance therapy following autologous stem cell transplantation. Myelodysplastic Syndromes (MDS): Specifically for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): For patients whose disease has relapsed or progressed after two prior therapies, one of which included Bortezomib. Follicular Lymphoma & Marginal Zone Lymphoma: In combination with Rituximab for previously treated adult patients. 2. Mechanism of Action: The Three-Tiered Defense Immune System Stimulation: It enhances the activation of T-cells and Natural Killer (NK) cells, significantly improving the body’s innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It inhibits the growth of new blood vessels (angiogenesis) within the bone marrow, effectively “starving“ the tumor of the nutrients and oxygen it needs to expand. Direct Tumor Suppression: It binds directly to the Cereblon E3 ubiquitin ligase complex, leading to the degradation of essential transcription factors (Aiolos and Ikaros) required for the survival of B-cell malignancies. 3. Administration and Dosing Cycle Management: Often prescribed in a 28-day cycle (e.g., 21 days on, 7 days off). Timing: The capsule should be taken at approximately the same time each day, with or without food. Handling: Capsules must be swallowed whole. They should not be opened, broken, or chewed. Clinical Side Effects & Safety Monitoring Hematological Toxicity: Significant risk of Neutropenia (low white blood cells) and Thrombocytopenia (low platelets). Weekly blood counts are typically required during the first several cycles. Venous Thromboembolism: Increased risk of deep vein thrombosis (DVT) and pulmonary embolism. Prophylactic anticoagulation is often recommended. Teratogenicity: CRITICAL WARNING: Lenalidomide is structurally related to thalidomide and can cause severe, life-threatening birth defects. Strict adherence to a regulated pregnancy prevention program is mandatory. Gastrointestinal: Diarrhea, constipation, nausea, and abdominal pain. General: Fatigue, muscle cramps, and skin rashes. Why Source Lenalieva 5mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Lenalieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and comprehensive B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Sunitcap 50mg Capsule: High-Potency Multi-Targeted Tyrosine Kinase Inhibition for Global Oncology Sourcing Are you searching for a verified Sunitcap 50mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that high-dose tyrosine kinase inhibitors (TKIs) reach healthcare providers with 100% pharmaceutical integrity. Detailed Product Profile: What is Sunitcap 50mg? Sunitcap 50mg is an oral, multi-targeted Tyrosine Kinase Inhibitor (TKI) containing the active pharmaceutical ingredient Sunitinib Malate. Manufactured by Allieva, the 50mg strength is the maximum dosage form, optimized for patients requiring intensive management of specific malignant tumors. It is designed to target the specific proteins that cancer cells utilize to grow, divide, and develop the blood vessels they need to survive. 1. Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): A primary systemic therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Specifically for patients whose disease has progressed on or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Used for progressive, well-differentiated tumors in patients with unresectable, locally advanced, or metastatic disease. Adjuvant Treatment: Utilized to reduce the risk of cancer recurring in adult patients at high risk of recurrence following nephrectomy (kidney surgery). 2. Mechanism of Action: The Dual-Action Blockade Anti-Angiogenesis: It blocks the Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This effectively “starves“ the tumor by preventing it from forming the new blood vessels required for nutrient and oxygen delivery. Direct Anti-Tumor Activity: It inhibits KIT (CD117), RET, and FLT3, which are signaling proteins that drive the uncontrolled multiplication of cancer cells. This combined inhibition stops the signaling pathways, leading to tumor shrinkage and significantly delayed disease progression. 3. Administration and Usage Dosing Schedule: For RCC and GIST, the standard schedule is often 50mg once daily for 4 weeks, followed by 2 weeks off. For pNET, it is typically taken as a continuous daily dose. Timing: Can be taken with or without food. Consistency in daily timing is key for maintaining therapeutic blood levels. Precautions: Patients must avoid grapefruit and grapefruit juice, as they can significantly increase the drug's concentration in the blood, leading to potential toxicity. Clinical Side Effects & Safety Monitoring Fatigue & Asthenia: High levels of tiredness are a common clinical observation, especially at the 50mg dose. Gastrointestinal Distress: Diarrhea, nausea, vomiting, stomatitis (mouth sores), and altered taste (dysgeusia). Dermatological Reactions: Hand-Foot Syndrome (redness, pain, or swelling on palms and soles), skin yellowing (non-jaundice), or changes in hair color. Hypertension: High blood pressure is a frequent side effect and must be medically managed. Hematological: Decreased blood counts (neutropenia, thrombocytopenia); regular blood tests are mandatory. Endocrine: Hypothyroidism (underactive thyroid) is a known side effect requiring periodic thyroid function tests (TFTs). Why Source Sunitcap 50mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Sunitcap with full batch-specific traceability and COA. Logistics Authority: Expert handling of import regulations for London (UK), the USA, Australia, and South Africa. Wholesale Fulfillment: Competitive bulk pricing and steady inventory for hospital groups, oncology networks, and regional distributors. Regulatory Compliance: Every shipment is accompanied by WHO-GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Sunitcap 25mg Capsule: Advanced Multi-Targeted Tyrosine Kinase Inhibition for Global Oncology Sourcing Are you searching for a verified Sunitcap 25mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical tyrosine kinase inhibitors (TKIs) reach healthcare providers with 100% pharmaceutical integrity. Detailed Product Profile: What is Sunitcap 25mg? Sunitcap 25mg is an oral, multi-targeted Tyrosine Kinase Inhibitor (TKI) containing the active pharmaceutical ingredient Sunitinib Malate. Manufactured by Allieva, this 25mg strength is a specialized formulation designed to target the specific proteins that cancer cells use to grow, divide, and develop the blood vessels they need to survive. 1. Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): A first-line therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Specifically for patients whose disease has progressed on or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Used for progressive, well-differentiated tumors in patients with unresectable, locally advanced, or metastatic disease. Adjuvant Treatment: In certain high-risk settings, it is used to reduce the risk of cancer returning after nephrectomy (kidney surgery). 2. Mechanism of Action: The Dual-Action Blockade Anti-Angiogenesis: It blocks the Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This effectively “starves“ the tumor by preventing it from forming the new blood vessels required for nutrient delivery. Direct Anti-Tumor Activity: It inhibits KIT (CD117), RET, and FLT3, which are signaling proteins that drive the uncontrolled multiplication of cancer cells. This combined inhibition stops the signaling pathways, leading to tumor shrinkage and delayed disease progression. 3. Administration and Usage Dosing Schedule: Often taken in a “4 weeks on, 2 weeks off“ cycle, or as a continuous daily dose depending on the specific clinical indication. Timing: Can be taken with or without food. Consistency in daily timing is key for maintaining therapeutic blood levels. Precautions: Patients should avoid grapefruit and grapefruit juice, as they can significantly increase the drug's concentration in the blood, leading to toxicity. Clinical Side Effects & Safety Monitoring Fatigue & Asthenia: High levels of tiredness are a common clinical observation. Gastrointestinal Distress: Diarrhea, nausea, vomiting, stomatitis (mouth sores), and altered taste (dysgeusia). Dermatological Reactions: Hand-Foot Syndrome (redness, pain, or swelling on palms and soles), skin yellowing (not jaundice), or changes in hair color. Hypertension: High blood pressure is a frequent side effect and must be managed medically. Hematological: Decreased blood counts (neutropenia, thrombocytopenia); regular blood tests are mandatory. Endocrine: Hypothyroidism (underactive thyroid) is a known side effect requiring periodic thyroid function tests. Why Source Sunitcap 25mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Sunitcap with full batch-specific traceability and COA. Logistics Authority: Expert handling of import regulations for London (UK), the USA, Australia, and South Africa. Wholesale Fulfillment: Competitive bulk pricing and steady inventory for hospital groups, specialty clinics, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp